Efficacy and Tolerability of a Combined Moxifloxacin/Dexamethasone Formulation for Topical Prophylaxis in Phacoemulsification: An Open-Label Single-Arm Clinical Trial

Table 1

Anterior chamber cells of operative eye, n (%).

Anterior chamber cells	Baseline	Day 1	Day 3	Day 8	Day 15
N	60	60	60	60	60
0 = Less than 5 cells	60 (100.0%)	2 (3.3%)	26 (43.3%)	49 (81.7%)	55 (91.7%)
1 = Mild: 5–10 cells	0 (0.0%)	25 (41.7%)	21 (35.0%)	9 (15.0%)	4 (6.7%)
2 = Moderate:11–20 cells	0 (0.0%)	24 (40.0%)	1 (20.0%)	2 (3.3%)	1 (1.7%)
3 = Marked: 21–50 cells	0 (0.0%)	9 (15.0%)	1 (1.7%)	0 (0.0%)	0 (0.0%)
4 = Severe: Greater than 50 cells/hypopyon	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)